Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.

Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, Kállay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P; EINSTEIN-Jr Phase 3 Investigators.

Lancet Haematol. 2019 Nov 4. pii: S2352-3026(19)30219-4. doi: 10.1016/S2352-3026(19)30219-4. [Epub ahead of print]

PMID:
31699660
2.

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.

Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaría A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D; EINSTEIN-Jr Phase 2 Investigators.

Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016/S2352-3026(19)30161-9. Epub 2019 Aug 13.

PMID:
31420317
3.

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.

Khan F, Rahman A, Carrier M, Kearon C, Weitz JI, Schulman S, Couturaud F, Eichinger S, Kyrle PA, Becattini C, Agnelli G, Brighton TA, Lensing AWA, Prins MH, Sabri E, Hutton B, Pinede L, Cushman M, Palareti G, Wells GA, Prandoni P, Büller HR, Rodger MA; MARVELOUS Collaborators.

BMJ. 2019 Jul 24;366:l4363. doi: 10.1136/bmj.l4363.

4.

Determinants of severe post-thrombotic syndrome: The role of thrombus location.

Prandoni P, Lensing AWA, Prins MH, Villalta S, Noventa F.

Thromb Res. 2019 Jun;178:171-172. doi: 10.1016/j.thromres.2019.04.001. Epub 2019 Apr 16. No abstract available.

PMID:
31035098
5.

Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.

Cate VT, Lensing AWA, Weitz JI, Beyer-Westendorf J, Wells PS, Mismetti P, Prandoni P, Cohen AT, Davidson BL, Prins MH.

Haematologica. 2019 Oct;104(10):e474-e477. doi: 10.3324/haematol.2018.209924. Epub 2019 Mar 7. No abstract available.

6.

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study.

Lensing AWA, Male C, Young G, Kubitza D, Kenet G, Patricia Massicotte M, Chan A, Molinari AC, Nowak-Goettl U, Pap ÁF, Adalbo I, Smith WT, Mason A, Thelen K, Berkowitz SD, Crowther M, Schmidt S, Price V, Prins MH, Monagle P.

Thromb J. 2018 Dec 21;16:34. doi: 10.1186/s12959-018-0188-y. eCollection 2018.

7.

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study.

Willmann S, Thelen K, Kubitza D, Lensing AWA, Frede M, Coboeken K, Stampfuss J, Burghaus R, Mück W, Lippert J.

Thromb J. 2018 Dec 4;16:32. doi: 10.1186/s12959-018-0185-1. eCollection 2018.

8.

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study.

Kubitza D, Willmann S, Becka M, Thelen K, Young G, Brandão LR, Monagle P, Male C, Chan A, Kennet G, Martinelli I, Saracco P, Lensing AWA.

Thromb J. 2018 Dec 4;16:31. doi: 10.1186/s12959-018-0186-0. eCollection 2018.

9.

Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis.

Chan A, Lensing AWA, Kubitza D, Brown G, Elorza D, Ybarra M, Halton J, Grunt S, Kenet G, Bonnet D, Santamaria A, Saracco P, Biss T, Climent F, Connor P, Palumbo J, Thelen K, Smith WT, Mason A, Adalbo I, Berkowitz SD, Hurst E, van Kesteren J, Young G, Monagle P.

Thromb J. 2018 Nov 1;16:29. doi: 10.1186/s12959-018-0182-4. eCollection 2018.

10.

Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.

Wells PS, Prins MH, Beyer-Westendorf J, Lensing AWA, Haskell L, Levitan B, Laliberté F, Ashton V, Xiao Y, Lejeune D, Crivera C, Lefebvre P, Zhao Q, Yuan Z, Schein J, Prandoni P.

Chest. 2018 Dec;154(6):1371-1378. doi: 10.1016/j.chest.2018.08.1059. Epub 2018 Sep 7.

11.

The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.

Ten Cate H, Lensing AWA, Weitz JI, Middeldorp S, Beyer-Westendorf J, Kubitza D, Brighton T, Raskob GE, Mismetti P, Prandoni P, Gebel M, Prins MH.

Thromb Res. 2018 Oct;170:75-83. doi: 10.1016/j.thromres.2018.08.008. Epub 2018 Aug 15.

PMID:
30121419
12.

Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.

Prandoni P, Lensing AWA, Prins MH, Gebel M, Pap AF, Homering M, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Cohen AT, Davidson BL, van Bellen B, Verhamme P, Wells PS, Yuan Z, Levitan B, Weitz JI.

Thromb Res. 2018 Aug;168:121-129. doi: 10.1016/j.thromres.2018.06.009. Epub 2018 Jul 10.

PMID:
30064683
13.

Risk of recurrent venous thromboembolism according to baseline risk factor profiles.

Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, Bauersachs R, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Kakkar AK, van Bellen B, Pap AF, Homering M, Tamm M, Weitz JI.

Blood Adv. 2018 Apr 10;2(7):788-796. doi: 10.1182/bloodadvances.2018017160.

14.

Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.

Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberté F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P.

J Med Econ. 2018 Jun;21(6):587-594. doi: 10.1080/13696998.2018.1444615. Epub 2018 Mar 16.

PMID:
29469638
15.

Does the presence of clinical symptoms of pulmonary embolism affect the outcome of patients with deep vein thrombosis?

Prandoni P, Lensing AWA, Prins MH, Noventa F, Villalta S.

Thromb Res. 2017 Sep;157:134-135. doi: 10.1016/j.thromres.2017.07.021. Epub 2017 Jul 21. No abstract available.

PMID:
28743057
16.

Extended Treatment of Venous Thromboembolism.

Weitz JI, Lensing AWA, Prins MH.

N Engl J Med. 2017 Jun 22;376(25):2491-2492. doi: 10.1056/NEJMc1705484. No abstract available.

PMID:
28636848
17.

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators.

N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18.

18.

Pulmonary Embolism in Patients Hospitalized for Syncope.

Prandoni P, Lensing AWA, Prins MH.

N Engl J Med. 2017 Feb 2;376(5):497. doi: 10.1056/NEJMc1615913. No abstract available.

PMID:
28146654
19.

Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.

Beyer-Westendorf J, Lensing AW, Arya R, Bounameaux H, Cohen AT, Wells PS, Middeldorp S, Verhamme P, Hughes R, Kucher N, Pap AF, Trajanovic M, Prins MH, Prandoni P, Weitz JI.

Thromb Res. 2017 Jan;149:29-37. doi: 10.1016/j.thromres.2016.11.014. Epub 2016 Nov 21.

PMID:
27886530
20.

Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope.

Prandoni P, Lensing AW, Prins MH, Ciammaichella M, Perlati M, Mumoli N, Bucherini E, Visonà A, Bova C, Imberti D, Campostrini S, Barbar S; PESIT Investigators.

N Engl J Med. 2016 Oct 20;375(16):1524-1531.

21.

Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.

Cheung YW, Middeldorp S, Prins MH, Pap AF, Lensing AW, Ten Cate-Hoek AJ, Villalta S, Milan M, Beyer-Westendorf J, Verhamme P, Bauersachs RM, Prandoni P; Einstein PTS Investigators Group.

Thromb Haemost. 2016 Sep 27;116(4):733-8. doi: 10.1160/TH16-01-0041. Epub 2016 Sep 1.

PMID:
27583311
22.

Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.

Di Nisio M, Vedovati MC, Riera-Mestre A, Prins MH, Mueller K, Cohen AT, Wells PS, Beyer-Westendorf J, Prandoni P, Bounameaux H, Kubitza D, Schneider J, Pisters R, Fedacko J, Fontes-Carvalho R, Lensing AW.

Thromb Haemost. 2016 Sep 27;116(4):739-46. doi: 10.1160/TH16-02-0087. Epub 2016 Aug 18.

PMID:
27535349
23.

Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.

Wells PS, Prins MH, Levitan B, Beyer-Westendorf J, Brighton TA, Bounameaux H, Cohen AT, Davidson BL, Prandoni P, Raskob GE, Yuan Z, Katz EG, Gebel M, Lensing AWA.

Chest. 2016 Nov;150(5):1059-1068. doi: 10.1016/j.chest.2016.05.023. Epub 2016 Jun 1.

PMID:
27262225
24.

Erratum to: 'Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program'.

Yamada N, Hirayama A, Maeda H, Sakagami S, Shikata H, Prins MH, Lensing AW, Kato M, Onuma J, Miyamoto Y, Iekushi K, Kajikawa M.

Thromb J. 2016 May 23;14:11. doi: 10.1186/s12959-016-0085-1. eCollection 2016.

25.

Post-thrombotic syndrome and the risk of subsequent recurrent thromboembolism.

Prandoni P, Noventa F, Lensing AW, Prins MH, Villalta S.

Thromb Res. 2016 May;141:91-2. doi: 10.1016/j.thromres.2016.03.010. Epub 2016 Mar 9. No abstract available.

PMID:
26986754
26.

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.

Kline JA, Jimenez D, Courtney DM, Ianus J, Cao L, Lensing AW, Prins MH, Wells PS.

Acad Emerg Med. 2016 Feb;23(2):144-50. doi: 10.1111/acem.12865. Epub 2016 Jan 14.

27.

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.

Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Trajanovic M, Gebel M, Lam P, Wells PS, Prins MH.

Blood. 2016 Mar 17;127(11):1417-25. doi: 10.1182/blood-2015-08-665927. Epub 2015 Dec 22.

28.

Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.

Kooistra HA, Gebel M, Sahin K, Lensing AW, Meijer K.

Thromb Haemost. 2015 Nov 25;114(6):1136-43. doi: 10.1160/TH14-12-1033. Epub 2015 Jul 30.

PMID:
26224199
29.

Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.

Eerenberg ES, Middeldorp S, Levi M, Lensing AW, Büller HR.

J Thromb Haemost. 2015 Sep;13(9):1590-6. doi: 10.1111/jth.13051. Epub 2015 Aug 22.

30.

Venous thrombotic burden and the risk of subsequent overt cancer.

Prandoni P, Lensing AW, Prins MH, Villalta S, Negri S, Piccioli A, Noventa F.

Thromb Haemost. 2015 Oct;114(4):864-5. doi: 10.1160/TH15-02-0146. Epub 2015 Jul 9. No abstract available.

PMID:
26155830
31.

Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.

Weitz JI, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Holberg G, Kakkar A, Lensing AW, Prins M, Haskell L, van Bellen B, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators.

Thromb Haemost. 2015 Aug 31;114(3):645-50. doi: 10.1160/TH15-02-0131. Epub 2015 May 21.

PMID:
25994838
32.

Residual vein thrombosis and the risk of subsequent serious complications.

Prandoni P, Lensing AW, Prins MH, Villalta S, Harenberg J, Noventa F.

Thromb Res. 2015 Jul;136(1):178-9. doi: 10.1016/j.thromres.2015.04.038. Epub 2015 May 8. No abstract available.

PMID:
25981139
33.

Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.

Matsuo H, Prins M, Lensing AW, Fujinuma EW, Miyamoto Y, Kajikawa M.

Curr Med Res Opin. 2015 Jun;31(6):1057-61. doi: 10.1185/03007995.2015.1037728. Epub 2015 May 11.

PMID:
25851062
34.

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program.

Yamada N, Hirayama A, Maeda H, Sakagami S, Shikata H, Prins MH, Lensing AW, Kato M, Onuma J, Miyamoto Y, Iekushi K, Kajikawa M.

Thromb J. 2015 Jan 17;13:2. doi: 10.1186/s12959-015-0035-3. eCollection 2015. Erratum in: Thromb J. 2016;14:11.

35.

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.

Fermann GJ, Erkens PM, Prins MH, Wells PS, Pap ÁF, Lensing AW.

Acad Emerg Med. 2015 Mar;22(3):299-307. doi: 10.1111/acem.12615. Epub 2015 Feb 25.

36.

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy.

Wells PS, Gebel M, Prins MH, Davidson BL, Lensing AW.

Thromb J. 2014 Nov 26;12:26. doi: 10.1186/1477-9560-12-26. eCollection 2014.

37.

The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation.

Prandoni P, Lensing AW, Prins MH, Pesavento R, Piccioli A, Sartori MT, Tormene D, Milan M, Vedovetto V, Noventa F, Villalta S, Harenberg J.

Semin Thromb Hemost. 2015 Mar;41(2):133-40. doi: 10.1055/s-0035-1544161. Epub 2015 Feb 15.

PMID:
25682083
38.

Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.

Prandoni P, Prins MH, Cohen AT, Müller K, Pap ÁF, Tewes MC, Lensing AW.

Acad Emerg Med. 2015 Feb;22(2):142-9. doi: 10.1111/acem.12585. Epub 2015 Feb 9.

39.

Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.

Prins MH, Bamber L, Cano SJ, Wang MY, Erkens P, Bauersachs R, Lensing AW.

Thromb Res. 2015 Feb;135(2):281-8. doi: 10.1016/j.thromres.2014.11.008. Epub 2014 Nov 18.

PMID:
25483215
40.

Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.

Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P.

Lancet Haematol. 2014 Oct;1(1):e37-46. doi: 10.1016/S2352-3026(14)70018-3. Epub 2014 Sep 28.

PMID:
27030066
41.

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.

Davidson BL, Verheijen S, Lensing AW, Gebel M, Brighton TA, Lyons RM, Rehm J, Prins MH.

JAMA Intern Med. 2014 Jun;174(6):947-53. doi: 10.1001/jamainternmed.2014.946.

PMID:
24733305
42.

Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.

van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW.

Curr Med Res Opin. 2014 May;30(5):829-37. doi: 10.1185/03007995.2013.879439. Epub 2014 Jan 22.

PMID:
24432872
43.

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.

Bauersachs RM, Lensing AW, Prins MH, Kubitza D, Pap ÁF, Decousus H, Beyer-Westendorf J, Prandoni P.

Thromb J. 2014 Nov 24;12:25. doi: 10.1186/1477-9560-12-25. eCollection 2014.

44.

Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.

Wang Y, Wang C, Chen Z, Zhang J, Liu Z, Jin B, Ying K, Liu C, Shao Y, Jing Z, Meng IL, Prins MH, Pap AF, Müller K, Lensing AW; Chinese EINSTEIN Investigators.

Thromb J. 2013 Dec 16;11(1):25. doi: 10.1186/1477-9560-11-25.

45.

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.

Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS; EINSTEIN Investigators.

Thromb J. 2013 Sep 20;11(1):21. doi: 10.1186/1477-9560-11-21.

46.

Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.

Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, Cano SJ.

Thromb Haemost. 2013 Oct;110(4):732-41. doi: 10.1160/TH13-03-0243. Epub 2013 Jul 11.

PMID:
23846019
47.
48.

Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.

Sarich TC, Peters G, Berkowitz SD, Misselwitz F, Nessel CC, Burton P, Cook-Bruns N, Lensing AW, Haskell L, Perzborn E, Kubitza D, Moore KT, Jalota S, Weber J, Pan G, Sun X, Westermeier T, Nadel A, Oppenheimer L, DiBattiste PM.

Ann N Y Acad Sci. 2013 Jul;1291:42-55. doi: 10.1111/nyas.12136. Epub 2013 May 23. Review.

PMID:
23701516
49.

Clot resolution after 3 weeks of anticoagulant treatment for pulmonary embolism: comparison of computed tomography and perfusion scintigraphy.

van Es J, Douma RA, Kamphuisen PW, Gerdes VE, Verhamme P, Wells PS, Bounameaux H, Lensing AW, Büller HR.

J Thromb Haemost. 2013 Apr;11(4):679-85. doi: 10.1111/jth.12150.

50.

Family history of venous thrombosis or sudden death as a risk factor for venous thromboembolism.

Prandoni P, Prins MH, Ghirarduzzi A, Pengo V, Sartori MT, Ugolotti MC, Bracco A, Veropalumbo MR, Noventa F, Lensing AW.

Thromb Haemost. 2012 Jun;107(6):1191-2. doi: 10.1160/TH11-12-0845. Epub 2012 Mar 22. No abstract available.

PMID:
22436905

Supplemental Content

Loading ...
Support Center